Imreg
Executive Summary
Firm met with FDA Commissioner Young and senior FDA staff July 20 to discuss the design of proposed further clinical trials for its AIDS therapeutic Imreg-1 and "when and under what circumstances during the second controlled trial of the drug, a treatment protocol might be initiated," the firm said Aug. 29. An FDA advisory committee concluded in April that the biologic's effect on ARC must be corroborated by further testing ("The Pink Sheet" April 10, T&G-1). Imreg-1's Treatment IND application for ARC patients was denied by the agency April 28 ("The Pink Sheet" May 15, T&G-12).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.